According to data from NIH and industry advocacy group BIOCOM, San Diego receives over 1 billion USD in NIH funding annually — a figure large enough to obscure a crack spreading underneath. Total funding remains stable, but the number of new grants awarded to research institutions here has declined from 776 to just 531 in just two years, as of the same point in the current fiscal year. That is not an adjustment — it is a sign of a pipeline gradually clogging.
This contradiction — Congress pumping money in, the executive branch tightening the spigot — sits at the heart of the story San Diego faces. And to understand why it is more dangerous than the surface numbers suggest, one must look at how NIH actually operates, not how people think it does.
NIH Is Not Just a Budget — It Is the World's Strictest Talent Selection Mechanism
NIH, as it has been designed since the 1940s, is not merely a money distribution agency. It is the world's most rigorous peer review mechanism. A scientist at UCSD submits a grant application, a panel of independent experts evaluates it, ranks it, and only the best proposals are selected. This process — consuming many months and requiring dozens of NIH staff to operate — is precisely what is breaking.
According to a report in the scientific journal Nature, NIH lost nearly 20 percent of its workforce in the past year due to layoffs and resignations. When the review machinery lacks personnel, new grant applications pile up. The result: as of over seven months into the current fiscal year, NIH nationwide has awarded less than half the number of new grants compared to the five-year average, according to NIH's own data. San Diego is no exception to this trend — 531 grants compared to 776 at the same point in 2024 is direct evidence.
This creates a peculiar paradox: Congress actually refused the Trump administration's proposed cuts of nearly 40 percent to NIH's budget, and even slightly increased funding for the current fiscal year — yet the money cannot be spent without people to process the paperwork. NIH Director Jay Bhattacharya committed to the House Budget Allocation Committee back in March 2026 that the agency would spend the entire 49 billion USD budget before the end of the fiscal year. That is a questionable commitment when the operating machinery is missing nearly one-fifth of its workforce.
The Real Blow Falls on the Next Generation of Researchers
The most overlooked part of this story is the impact on early-career researchers — and this is precisely where the Vietnamese American community is being directly affected.
San Diego is one of the country's life sciences centers with the highest concentration of Asian American and Vietnamese American researchers. Many of them are in early career stages — postdocs, assistant professors, or researchers at institutes like Scripps, Salk, or Sanford Burnham Prebys. This group depends most heavily on new grants, because they lack a history of old grants to live on.
According to research published by scientists at UCSD and other institutions, the wave of funding cancellations related to the Trump administration's order eliminating "DEI" programs has had disproportionate impact on minority researchers. Many canceled projects were not diversity programs — they were medical research on specific communities, including research on health of Asian Americans, people of color, and women. When these topics are erased, not only does funding disappear — the entire research field shrinks.
For Vietnamese Americans in the biosciences, this means something concrete: a cancer researcher at UCSD sees a grant canceled while watching colleagues leave the lab due to lost salaries. NBC7 San Diego has documented NIH cutting tens of millions of dollars in cancer research funding at UCSD and other research institutes in the region. These are not abstract numbers — these are halted experiments, delayed clinical trials, and young scientists forced to find work elsewhere.
San Diego's Economy Cannot Absorb This Forever
The life sciences industry is San Diego's economic pillar in a way very different from other sectors. According to BIOCOM, the industry comprises over 2,000 companies and contributes 167,000 jobs — more than 10 percent of the county's workforce. But more importantly is its structure: most startups in this industry are born from laboratories at UCSD, Scripps, or Salk. NIH funding is seed capital — it does not just pay the scientist's salary, it generates patents, spinoffs, and ultimately income tax and jobs for the county.
In 2025, according to NIH data, UCSD received 576 million USD, Scripps Research received 164 million USD, Salk received 61 million USD, and Sanford Burnham Prebys received 45 million USD. San Diego County ranks ninth nationally in total NIH funding received. These numbers remain stable in 2025 — but largely because they represent disbursements from grants awarded in previous years. When the new funding pipeline shrinks, the true consequences will only appear in a few years.
One technical detail in the funding report deserves attention: NIH recently tends to disburse the full grant value upfront, rather than distributing it evenly across years as was customary. This may explain why the total funding for San Diego through mid-2026 remains equivalent to the previous year — but is actually "paying forward" from later years. If that is accurate, those stable numbers are a short-term financial illusion, not a sign of the industry's true health.
California Bets Big, But the Gamble Is Not Yet Certain to Win
In that context, California's proposal to establish its own life sciences research agency — known as S.B. 895, modeled on NIH at the state level, with a budget of 12 billion USD in bonds requiring voter approval — is the most serious policy response Sacramento has produced.
California is no newcomer to this game. In 2004, the state approved Proposition 71, authorizing 3 billion USD in bonds to fund stem cell research — a direct response to the Bush administration's restrictions on stem cell research. The California Institute for Regenerative Medicine (CIRM) was established from it and has accompanied hundreds of research projects over two decades. That precedent shows California is prepared and capable of replacing federal funding when necessary.
But S.B. 895 must clear much higher hurdles than Proposition 71. First, 12 billion USD is four times the scale of the 2004 bond — and this occurs as California struggles with budget deficits. Second, voters must approve this bond in a context of much higher borrowing costs than 2004. Third, building a state-level scientific funding infrastructure with capacity equivalent to NIH — including a peer review system, governance, and disbursement — is an institutional problem that cannot be solved in one or two years.
To be blunt: even if S.B. 895 passes and voters approve it, it cannot make up for what is being lost right now. Young researchers cannot wait until bonds are issued and funding councils are established. The narrowest and most dangerous moment of this story lies here: the damage from losing scientific talent cannot be reversed in the short term.
The Gap Washington Leaves Will Not Wait for Sacramento
Ultimately, the real question is not whether San Diego will survive through 2026 — it very likely will. The question is: how many generations of scientists will never be formed?
The new NIH funding pipeline — grants being awarded today — are the scientific discoveries of the next 5 to 10 years, are the drugs approved in the 2030s, are the startups founded from doctoral dissertations in 2027. When new grant numbers drop from 776 to 531 in one and a half years, that impact will only appear clearly on the county's balance sheet around 2029 to 2032.
From a political angle, Congress — including the Republican majority — has shown unwillingness to cut NIH at the level the Trump administration proposed. When Director Bhattacharya faced skepticism from bipartisan senators about a proposal to cut another nearly 6 billion USD back in May 2026, that was a clear signal that NIH's budget will not be destroyed through legislation. The real danger comes from within: the disintegration of the operating machinery, the departure of experienced personnel, and accumulated delays in the funding cycle — things that need no vote to cause damage.
For San Diego's Vietnamese American community — many of whom are either scientists, or have children studying or working in the biosciences — this means very real pressure: stay and endure instability, or seek opportunity in Boston, New York, or even Singapore and South Korea, places actively recruiting American scientists while Washington ties its own hands.
San Diego built its position as a world-leading life sciences center through decades of patient investment. Destroying it does not require a sudden policy decision — just enough delays, enough uncertainty, and enough talented young scientists deciding it is not worth waiting.